Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions

Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage in a streptozotoc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	TURKISH JOURNAL OF MEDICAL SCIENCES 2019-10, Vol.49 (5), p.1582-1589
Hauptverfasser:	Oltulu, Fatih, Buhur, Aylin, Gürel, Çevik, Kuşçu, Gökçe Cerren, Dağdeviren, Melih, Karabay Yavaşoğlu, Nefise Ülkü, Köse, Timur, Yavaşoğlu, Altuğ
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antihypertensive Agents - administration & dosage Diabetes Complications - prevention & control Diabetes Mellitus, Experimental - metabolism Liver Diseases - prevention & control Losartan - administration & dosage Male NF-kappa B - biosynthesis NF-kappa B - drug effects Nitric Oxide Synthase Type II - biosynthesis Nitric Oxide Synthase Type II - drug effects Nitric Oxide Synthase Type III - biosynthesis Nitric Oxide Synthase Type III - drug effects Rats Rats, Wistar Vascular Endothelial Growth Factor A - biosynthesis Vascular Endothelial Growth Factor A - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!